- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 428KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 71KB)
Pembrolizumab – July 2023
Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
27 October 2023